These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 23006002

  • 21. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
    Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):1781-95. PubMed ID: 15771424
    [Abstract] [Full Text] [Related]

  • 22. Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).
    Bromidge SM, Clarke SE, Gager T, Griffith K, Jeffrey P, Jennings AJ, Joiner GF, King FD, Lovell PJ, Moss SF, Newman H, Riley G, Rogers D, Routledge C, Serafinowska H, Smith DR.
    Bioorg Med Chem Lett; 2001 Jan 08; 11(1):55-8. PubMed ID: 11140733
    [Abstract] [Full Text] [Related]

  • 23. The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.
    Zajdel P, Kurczab R, Grychowska K, Satała G, Pawłowski M, Bojarski AJ.
    Eur J Med Chem; 2012 Oct 08; 56():348-60. PubMed ID: 22926225
    [Abstract] [Full Text] [Related]

  • 24. Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M, Marcinkowska M, Bucki A, Pawłowski M, Mitka K, Jaśkowska J, Kowalski P, Kazek G, Siwek A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P.
    J Med Chem; 2014 Jun 12; 57(11):4543-57. PubMed ID: 24805037
    [Abstract] [Full Text] [Related]

  • 25. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
    van Loevezijn A, Venhorst J, Iwema Bakker WI, de Korte CG, de Looff W, Verhoog S, van Wees JW, van Hoeve M, van de Woestijne RP, van der Neut MA, Borst AJ, van Dongen MJ, de Bruin NM, Keizer HG, Kruse CG.
    J Med Chem; 2011 Oct 27; 54(20):7030-54. PubMed ID: 21866910
    [Abstract] [Full Text] [Related]

  • 26. Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.
    Brodney MA, Johnson DE, Sawant-Basak A, Coffman KJ, Drummond EM, Hudson EL, Fisher KE, Noguchi H, Waizumi N, McDowell LL, Papanikolaou A, Pettersen BA, Schmidt AW, Tseng E, Stutzman-Engwall K, Rubitski DM, Vanase-Frawley MA, Grimwood S.
    J Med Chem; 2012 Nov 08; 55(21):9240-54. PubMed ID: 22974325
    [Abstract] [Full Text] [Related]

  • 27. Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor.
    Moloney GP, Martin GR, Mathews N, Milne A, Hobbs H, Dodsworth S, Sang PY, Knight C, Williams M, Maxwell M, Glen RC.
    J Med Chem; 1999 Jul 15; 42(14):2504-26. PubMed ID: 10411472
    [Abstract] [Full Text] [Related]

  • 28. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).
    Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M.
    J Med Chem; 2012 May 24; 55(10):4806-23. PubMed ID: 22468936
    [Abstract] [Full Text] [Related]

  • 29. Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.
    Trani G, Baddeley SM, Briggs MA, Chuang TT, Deeks NJ, Johnson CN, Khazragi AA, Mead TL, Medhurst AD, Milner PH, Quinn LP, Ray AM, Rivers DA, Stean TO, Stemp G, Trail BK, Witty DR.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5698-700. PubMed ID: 18793848
    [Abstract] [Full Text] [Related]

  • 30. Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands.
    Furlotti G, Alisi MA, Apicella C, Capezzone de Joannon A, Cazzolla N, Costi R, Cuzzucoli Crucitti G, Garrone B, Iacovo A, Magarò G, Mangano G, Miele G, Ombrato R, Pescatori L, Polenzani L, Rosi F, Vitiello M, Di Santo R.
    J Med Chem; 2012 Nov 26; 55(22):9446-66. PubMed ID: 23043420
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of benzoisothiazole derivatives possessing N,N-dimethylformimidamide group as 5-HT₆ receptor antagonists.
    Yoo E, Hayat F, Rhim H, Park Choo HY.
    Bioorg Med Chem; 2012 Apr 15; 20(8):2707-12. PubMed ID: 22405919
    [Abstract] [Full Text] [Related]

  • 32. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S.
    J Med Chem; 2003 Feb 27; 46(5):702-15. PubMed ID: 12593651
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors.
    Liu F, Majo VJ, Prabhakaran J, Milak MS, John Mann J, Parsey RV, Kumar JS.
    Bioorg Med Chem; 2011 Sep 01; 19(17):5255-9. PubMed ID: 21821420
    [Abstract] [Full Text] [Related]

  • 34. Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.
    Tripathy R, McHugh RJ, Bacon ER, Salvino JM, Morton GC, Aimone LD, Huang Z, Mathiasen JR, DiCamillo A, Huffman MJ, McKenna BA, Kopec K, Lu LD, Qian J, Angeles TS, Connors T, Spais C, Holskin B, Duzic E, Schaffhauser H, Rossé GC.
    Bioorg Med Chem Lett; 2012 Feb 01; 22(3):1421-6. PubMed ID: 22226656
    [Abstract] [Full Text] [Related]

  • 35. Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT₇ receptor antagonist activity.
    Volk B, Gacsályi I, Pallagi K, Poszávácz L, Gyönös I, Szabó E, Bakó T, Spedding M, Simig G, Szénási G.
    J Med Chem; 2011 Oct 13; 54(19):6657-69. PubMed ID: 21859099
    [Abstract] [Full Text] [Related]

  • 36. Extended N-Arylsulfonylindoles as 5-HT₆ Receptor Antagonists: Design, Synthesis & Biological Evaluation.
    Vera G, Lagos CF, Almendras S, Hebel D, Flores F, Valle-Corvalán G, Pessoa-Mahana CD, Mella-Raipán J, Montecinos R, Recabarren-Gajardo G.
    Molecules; 2016 Aug 16; 21(8):. PubMed ID: 27537868
    [Abstract] [Full Text] [Related]

  • 37. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
    Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL.
    J Med Chem; 2007 May 17; 50(10):2297-300. PubMed ID: 17441705
    [Abstract] [Full Text] [Related]

  • 38. Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket.
    van Loevezijn A, Venhorst J, Iwema Bakker WI, Lange JHM, de Looff W, Henzen R, de Vries J, van de Woestijne RP, den Hartog AP, Verhoog S, van der Neut MAW, de Bruin NMWJ, Kruse CG.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1605-1611. PubMed ID: 26876931
    [Abstract] [Full Text] [Related]

  • 39. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B, Bonnaud B, Funes P, Jubault N, Koek W, Assié MB, Cosi C, Kleven M.
    J Med Chem; 1999 May 06; 42(9):1648-60. PubMed ID: 10229633
    [Abstract] [Full Text] [Related]

  • 40. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S, Egner BJ, Gradén H, Gradén J, Morgan DG, Inghardt T, Giordanetto F.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4274-9. PubMed ID: 19500982
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.